文献速递肝病消化道肿瘤与早癌

同基因小鼠肝细胞癌肿瘤模型图谱分析:理解抗PD-1敏感肿瘤微环境的框架

Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
PubMed 文献 · Hepatology · 2023-04-17

本研究利用成像质谱流式与悬浮飞行时间流式技术,对Hep53.4、Hepa 1-6、RIL-175和TIBx四种同基因小鼠肝细胞癌模型的肿瘤微环境进行图谱分析。四种模型的免疫肿瘤微环境各异,原位肝肿瘤基线存在多种免疫抑制通路;TIBx对anti-PD-1治疗耐药,含高比例「M2样」肿瘤相关巨噬细胞。TCGA分析显示Hep53.4、RIL-175和TIBx的基线免疫特征广泛代表人类肝细胞癌,而Hepa 1-6不能重现绝大多数人类肝细胞癌的免疫肿瘤微环境。

要点

  • 四种同基因小鼠肝细胞癌模型的免疫肿瘤微环境存在差异,原位肝肿瘤基线存在多种免疫抑制通路。
  • TIBx模型对anti-PD-1治疗耐药,含高比例「M2样」肿瘤相关巨噬细胞。
  • Hep53.4、RIL-175和TIBx的基线免疫特征广泛代表人类肝细胞癌,Hepa 1-6则不能。

核心结论

  • 临床前模型与人类肝细胞癌的免疫肿瘤微环境存在广泛多样性,强调需使用多种同基因肝细胞癌模型以增进对通过免疫调节治疗肝细胞癌的理解。

研究设计与样本

  • 研究采用成像质谱流式与悬浮飞行时间流式等多层面方法,对Hep53.4、Hepa 1-6、RIL-175和TIBx(TIB-75的衍生物)四种同基因小鼠肝细胞癌模型的肿瘤微环境进行图谱分析。

主要发现

  • 四种模型的免疫肿瘤微环境各异,来自这些模型的原位肝肿瘤基线存在多种免疫抑制通路。
  • TIBx对anti-PD-1治疗耐药,含高比例「M2样」肿瘤相关巨噬细胞,具有削弱抗肿瘤免疫的潜力。
  • 对癌症基因组图谱(TCGA)的分析显示,Hep53.4、RIL-175和TIBx的基线免疫特征广泛代表人类肝细胞癌。
  • Hepa 1-6不能重现绝大多数人类肝细胞癌的免疫肿瘤微环境。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The treatment of hepatocellular carcinoma (HCC) has been transformed by the use of immune checkpoint inhibitors. However, most patients with HCC do not benefit from treatment with immunotherapy. There is an urgent need to understand the mechanisms that underlie response or resistance to immunotherapy for patients with HCC. The use of syngeneic mouse models that closely recapitulate the heterogeneity of human HCC will provide opportunities to examine the complex interactions between cancer cells and nonmalignant cells in the tumor microenvironment. APPROACH AND RESULTS: We leverage a multifaceted approach that includes imaging mass cytometry and suspension cytometry by time of flight to profile the tumor microenvironments of the Hep53.4, Hepa 1-6, RIL-175, and TIBx (derivative of TIB-75) syngeneic mouse HCC models. The immune tumor microenvironments vary across these four models, and various immunosuppressive pathways exist at baseline in orthotopic liver tumors derived from these models. For instance, TIBx, which is resistant to anti-programmed cell death protein 1 therapy, contains a high proportion of "M2-like" tumor-associated macrophages with the potential to diminish antitumor immunity. Investigation of The Cancer Genome Atlas reveals that the baseline immunologic profiles of Hep53.4, RIL-175, and TIBx are broadly representative of human HCCs; however, Hepa 1-6 does not recapitulate the immune tumor microenvironment of the vast majority of human HCCs. CONCLUSIONS: There is a wide diversity in the immune tumor microenvironments in preclinical models and in human HCC, highlighting the need to use multiple syngeneic HCC models to improve the understanding of how to treat HCC through immune modulation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zabransky DJ, Danilova L, Leatherman JM, et al. Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments. Hepatology. 2023. PMID: 35941803. doi:10.1002/hep.32707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。